A monoclonal antibody-inhibiting FMLP-induced chemotaxis of human neutrophils.
A monoclonal IgG1 antibody, termed NCD3, was raised against human neutrophils and has been shown to inhibit neutrophil chemotaxis. NCD3 displayed a considerable degree of stimulus specificity in that it inhibited N-formyl-methionyl-leucyl-phenylalanine- (FMLP) induced chemotaxis up to 80%, C5a and zymosan-activated plasma induced chemotaxis by only 20% and had no effect on leukotriene B4- (LTB4) or casein-mediated chemotaxis. NCD3 did not inhibit granule enzyme release from neutrophils in response to stimulation by various secretagogues, including FMLP, in the presence or absence of cytochalasin B (CB). Neutrophil phagocytosis of 51Cr-labeled opsonized sheep erythrocytes (51Cr-EAC) and superoxide anion (O2-) production in response to FMLP or phorbol myristate acetate (PMA) stimulation were not affected by pretreating cells with NCD3. Divalency of NCD3 was necessary for inhibition of chemotaxis, suggesting a requirement for cross-linking of the antigenic determinants on the neutrophil membrane surface.
D000706:Anaphylatoxins; D000818:Animals; D000911:Antibodies, Monoclonal; D001666:Binding Sites, Antibody; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D003182:Complement C5; D015936:Complement C5a; D003594:Cytoplasmic Granules / Q000201:enzymology; D006801:Humans; D007074:Immunoglobulin G / Q000145:classification; D008715:Methionine / Q000031:analogs & derivatives*; D051379:Mice; D008807:Mice, Inbred BALB C; D009239:N-Formylmethionine / Q000031:analogs & derivatives* / Q000494:pharmacology; D009240:N-Formylmethionine Leucyl-Phenylalanine; D009504:Neutrophils; D009842:Oligopeptides / Q000494:pharmacology*; D015054:Zymosan / Q000494:pharmacology
D000706:Anaphylatoxins; D000911:Antibodies, Monoclonal; D003182:Complement C5; D007074:Immunoglobulin G; D009842:Oligopeptides; D009239:N-Formylmethionine; D009240:N-Formylmethionine Leucyl-Phenylalanine; D015936:Complement C5a; D015054:Zymosan; D008715:Methionine